Physician profile
Jonathan A Eck
NPI 1821229949
$1,821.35
in general payments reported to CMS, 2019-2025
18 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.01 · 2020: $176 · 2021: $211 · 2022: $431 · 2023: $272 · 2024: $297 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $237.11 | 2019-2025 | |
| Biotissue Holdings INC. | $216.71 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $173.59 | 2019-2024 | Cequa |
| Alcon Vision LLC | $146.23 | 2019-2025 | Clareon, Rocklatan |
| Rxsight INC | $140.64 | 2022-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $132.71 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $112.47 | 2025 | Xdemvy |
| Coopervision INC. | $108.39 | 2022-2024 | Myday Contact Lens |
| Abbvie INC. | $103.01 | 2022-2023 | Xen Glaucoma Treatment System |
| Kala Pharmaceuticals, INC. | $95.52 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $87.77 | 2022-2025 | Infuse, Vyzulta |
| Abb Con-Cise Optical Group LLC | $67.86 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Aerie Pharmaceuticals, INC. | $48.56 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $44.45 | 2022-2023 | Cirrus Hd-Oct |
| Harrow Eye, LLC | $36.60 | 2023 | Iheezo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synergeyes, INC. | $35.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $18.53 | 2020 | |
| Kerecis Limited | $15.90 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Eck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.